RSV clinical trials at UCSF

2 research studies open to eligible people

Showing trials for

  • Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

    open to eligible people ages up to 2 years

    The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated through the matrix metalloproteinase (MMP)-9 pathway.

    San Francisco, California and other locations

  • Obeldesivir to Treat Nonhospitalized Adults With Acute Respiratory Syncytial Virus (RSV) Infection

    open to eligible people ages 18 years and up

    The goal of this clinical study is to learn more about the study drug, obeldesivir (ODV; GS-5245), and how safe and effective it is in treating nonhospitalized adults with acute respiratory syncytial virus (RSV) infection. The researchers want to see if obeldesivir can help participants' symptoms get better faster. The primary objectives of this study are to evaluate the efficacy of ODV in reducing the duration of symptoms and to evaluate the safety and tolerability of ODV in nonhospitalized adult participants with acute RSV infection.

    Fresno, California and other locations

Our lead scientists for RSV research studies include .

Last updated: